Archives

Innovestor makes follow-on investment in Ruokaboksi, leading Finnish meal-kit delivery provider

Innovestor

With the growing trend of consumers moving their purchases to e-commerce sites, the online grocery market has grown rapidly. Although the Finnish market is still smaller compared to our Nordic neighbours, it is catching up fast. Within this segment, and particularly in covid-19 stricken times, subscription-based FoodTech platforms have experienced sharp increases in sales.

Ruokaboksi’s service is based on a weekly subscription meal box, which is delivered straight to the customers door and includes all the ingredients with dinner recipes needed for the week. The company has 3 different sized meal boxes to choose from, based on preferences for e.g. vegetarian or child-friendly recipes. Also the number of recipes can be altered.

By delivering ready-made meal boxes with all the ingredients needed to prepare dinner, the service eases everyday by eliminating the age-old question of ‘what to eat today’ and cuts down the hassle of supermarket trips. Especially in the current covid-19 climate, services such as Ruokaboksi’s allow customers to stay safe at home as much as possible.

The co-founding team lead by CEO Juhana Rintala came up with the idea and joined forces when they all had small children, and were looking for ways to handle the weekly food shopping in a stress-free way.

“We see that rapid growth is needed in this is the type of business. With Innovestor’s help we have been able to invest in marketing and sales, aspects needed for growth. During our first year of operation, our revenue was around 200–300k euro, in June it was around 3 million euro. By the end of this year, we forecast our revenue will hit close to 10 million euro. Our growth curve continues to be quite steep” stated Ruokaboksi’s CEO Juhana Rintala.

 

Ruokaboksi

Innovestor was lead investor in Ruokaboksi’s seed funding round in 2018. Since then the team has made great headway on their growth plans, resulting in us now making a follow-on investment during the summer of 2020. We were joined by the company’s previous investors, Korpi Capital and Reaktor Ventures, bringing the total funding round to 600k euro.

“The company has continued to execute strongly in a very interesting market, and we are glad support the company into their next growth phase” commented Innovestor’s Wilhelm Lindholm.

 

For more information: 

Juhana Rintala

CEO, Ruokaboksi

juhana.rintala(a)ruokaboksi.fi +358 45 2268320

 

Wilhelm Lindholm

Managing Partner, Innovestor Ltd.

wilhelm.lindholm(a)innovestor.fi +358 40 5811051

 

Ruokaboksi in the Media:

Koronakriisi mullisti ruoan verkkokaupan – myös ateriakassien myynti on moninkertaistunut: ”Meillä keräily ei ruuhkaudu”

Ruoan verkkokauppa ja kirjolohen kasvattaja pörssiin?– Katso pääomasijoittajien tuore lista 54 mahdollisesta pörssilistautujasta

Categories: News

Tags:

Scenic Biotech Enters into Genetic Modifier Collaboration with Genentech

Inkef Capital

  • Multi-year strategic collaboration in target discovery and therapeutic development based on Scenic Biotech’s disease modifying approach
  • Utilises Scenic’s unique Cell-Seq platform and its proprietary data warehouse of genetic modifiers
  • Scenic Biotech will receive an undisclosed upfront payment and is eligible to receive milestone payments and royalties across multiple products meeting certain pre-defined conditions

 

Amsterdam, The Netherlands, September 20, 2020 – Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that it has entered into a multi-year strategic collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialize novel therapeutics that target genetic modifiers.

Genetic modifiers are genes that counteract the effect of a disease-causing gene. They may explain why some people with genetic mutations linked to severe disease end up having only mild or no symptoms. Also known as disease suppressors, genetic modifiers therefore positively influence the severity of disease and act as a ‘natural form of protection’. Their discovery is leading to a completely new class of drug targets.

Under the terms of the agreement, Scenic will utilize its Cell-Seq platform and its data warehouse of genetic modifiers to identify drug targets in multiple therapeutic areas. The collaboration enables Genentech to select multiple targets for further development with an option to extend the collaboration. Scenic will receive an undisclosed upfront payment and is eligible to receive additional target selection fees for drug targets taken forward by Genentech. In addition, Scenic is eligible for success-based payments for each target based on achievement of certain predetermined milestones, as well as royalties on sales of certain products resulting from the collaboration. Total deal value could exceed US $375M.

Scenic has built an extensive proprietary data warehouse of genetic modifiers and its Cell-Seq platform enables the development of potential disease modifying therapeutics for devastating diseases with an in-house focus on inherited rare diseases and immuno-oncology/inflammation.

The Company was founded in 2017 as a spin-out of the Netherlands Cancer Institute, and Oxford University and recently appointed Oscar Izeboud, PhD as its Chief Executive Officer.

 

Dr Sebastian Nijman, Co-founder and CSO of Scenic Biotech said:

“Genentech is the pioneer in innovative biotech and has world leading research and development capabilities. Scenic is a science-driven company and having Genentech as our first major industry partner is a great validation of our technology and by working together it will extend the utility of our platform beyond our current therapeutic areas of interest. The collaboration also brings significant strategic value for Scenic as it enables us to realise the potential of our genetic modifier expertise alongside independently advancing our own programs towards clinical development.”

 

About Scenic Biotech

Scenic Biotech is focused on identifying genetic modifiers, a completely new class of disease targets, for drug intervention. Also known as disease suppressors, genetic modifiers are genes that act to suppress or completely block the effect of a disease-causing mutated gene.

As a pioneer in the field, Scenic Biotech is building the largest proprietary data warehouse of genetic modifiers and has already identified a number of novel genetic modifiers for over a dozen inherited diseases. This approach is enabling the development of disease modifying therapeutics for devastating diseases including inherited rare diseases and cancer.

Scenic Biotech is headquartered in Amsterdam, the Netherlands. The Company was founded in 2017 as a spin-out of the Netherlands Cancer Institute, and Oxford University, backed by a Dutch-UK syndicate of Venture Capital investors that include BioGeneration Ventures, Inkef Capital, and Oxford Sciences Innovation.

Scenic Biotech refers to all companies within the Scenic group, comprising Scenic Holding BV and its two fully owned subsidiary companies: Scenic Immunology BV and Scenic Biotech BV.

For further information please visit: www.scenicbiotech.com

Categories: News

Tags:

Ionir Launches Cloud Native Storage and Data Platform for Kubernetes with $11M in Funding led by JVP

C5 Capital

ntroduces industry first solution for instant mobility of applications and data between clouds

Press Release provided by Ionir—

New York, NY. – September 21, 2020 –Ionir launched today its container native  software defined storage and data management platform, designed to support Kubernetes production workloads in private cloud, hybrid cloud, and multi-cloud deployments.  The Ionir enterprise software defined storage platform delivers  Data Teleport™, the industry’s first instant mobility capability for persistent volumes, that allows stateful applications to be copied or moved instantly between Kubernetes clusters. Ionir also announced $11 million in funding led by Jerusalem Venture Partners (JVP) alongside C5 Capital.

The Ionir solution brings the same portability and mobility that customers get with containers and Kubernetes to data and persistent volumes. Based on the unique and proven technology developed by Reduxio, the Ionir’s platform eliminates the complexity of storage and data management for Kubernetes based clouds by allowing customers to build a seamless data layer and a common set of data management workflows independent of the underlying cloud or infrastructure.

“With Data Teleport, persistent volumes can be moved or copied between Kubernetes clusters and clouds in under 40 seconds independent of the size of the volume or the amount of data involved” said Jacob Cherian, CEO, Ionir. For example, in a production/development hybrid deployment, developers will no longer have to wait for hours or days for volumes to be copied to get access to the latest data. With instant mobility data can be refreshed in under a minute accelerating development processes and the delivery of new capabilities.”

The Ionir platform is the first microservices based software defined storage and data management solution for Kubernetes that allows the platform to be extended to support future interfaces and technologies without the need for fork-lift upgrades. The platform today provides the following capabilities:

  • Fully virtualized persistent volumes with no practical size limit
  • Data Teleport™ – Instantly copy or move volumes of any size across clouds
  • Instant clones for data and application recovery
  • Global deduplication and compression for efficiency at scale
  • Fault tolerant and highly available

 

“As a long standing investor in the cloud and infrastructure space, we have a track record of investing in companies that deliver the most innovative solution in the market to the world’s leading enterprises” said Fiona Darmon, General Partner, JVP and Ionir Board Member. “We are proud to lead this round in Ionir, leveraging the proven Reduxio technology, bringing about a new era of data democratization as organizations the world over will have the freedom to choose and move data freely between their cloud silos.”

Enterprise adoption of Kubernetes is increasing; but using legacy storage solutions and the lack of instant data mobility creates infrastructure silos and operational challenges in private cloud, hybrid cloud and multi-cloud deployments. Ionir’s platform and instant data mobility capability  allows enterprises to unify multiple infrastructure environments into a single data cloud with seamless mobility of applications and data.

“Ionir is disrupting the Kubernetes and cloud data storage market by helping organizations achieve seamless mobility for their applications and data” said Michael Wall, Chairman of Ionir, and a storage and IT infrastructure industry veteran. “This technology will redefine IT workflows and open up new possibilities for customers to maximize the return on their investments in multi-datacenter, hybrid cloud, and multi-cloud strategies.”

For more information about Ionir, the company’s vision, and to request a demo of the product and Data Teleport™ please visit www.ionir.com

About Ionir

Ionir’s cloud native storage and data management platform for Kubernetes combines high performance software-defined container-native storage and data management with data mobility to enable customers to build a single data cloud for their applications across all their infrastructure, anywhere. Ionir is backed by leading international VC funds Jerusalem Venture Partners (JVP) and C5 Capital, among others.  For more information, visit www.ionir.com Connect with Ionir on LinkedIn, Twitter, and Facebook.

Categories: News

Tags:

GeneWerk GmbH Announces Growth Equity Investment from Ampersand Capital Partners

GeneWerk will expand capabilities to meet rapidly growing demand for cell and gene therapy testing services

HEIDELBERG, Germany, Sept. 21, 2020 /PRNewswire/ — GeneWerk GmbH, a cell and gene therapy testing laboratory focused on providing preclinical and clinical trial patient sample analysis services, today announced a majority investment from Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the healthcare sector.  Ampersand’s growth investment will be used to expand GeneWerk’s capabilities to meet rapidly growing demand for cell and gene therapy testing services.

GeneWerk provides cell and gene therapy sponsors with patient testing services in compliance with guidance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).  The company is recognized as a leading provider of vector integration site analysis (ISA) services, a method that was developed by GeneWerk’s founders and that the FDA and EMA recommend performing after the administration of both integrating and non-integrating cell and gene therapies.  The company’s test menu also includes vector persistence testing, gene edited off-target analysis, vector copy number (VCN), vector quality control, immune repertoire analysis, and dedicated bioinformatics studies.  With a focus on vector safety, characterization, and functionality analysis, the company’s 30 employees work in compliance with GCP and in line with GLP standards in a BSL-2 classified state-of-the-art genomics and bioinformatics laboratory in Heidelberg, Germany.

Annette Deichmann, Ph.D., Co-Founder and Co-CEO at GeneWerk commented, “With the benefit of Ampersand as our partner, GeneWerk will strengthen and expand its position in the U.S. and European markets while further investing in our testing capabilities to service cell and gene therapy sponsors and patients.”  Co-Founder and Co-CEO Manfred Schmidt, Ph.D., then added, “Our partnership with Ampersand solidifies GeneWerk’s position in the space and will allow the company to continue to exceed our customers’ expectations by facilitating the development of innovative cell and gene therapies.  We are very pleased to have Ampersand on board as we take GeneWerk through its next phase of growth.” Christof von Kalle, M.D., Co-Founder concluded, “This will greatly further GeneWerk’s opportunities to contribute to medical breakthroughs and patient safety.”

Marina Pellon-Consunji, Principal at Ampersand said, “GeneWerk is a leading company in its field.  Given the exciting developments within the cell and gene therapy market and recent guidance by FDA and EMA, this is an excellent time for an investor with deep experience in cell and gene therapy to partner with the company.  We are looking forward to working with the team at GeneWerk to accelerate and continue its success in delivering leading testing services to ensure the safety of patients receiving cutting edge cell and gene therapies.”

About GeneWerk GmbH

Founded in 2014 by Prof. Dr. Christof von Kalle, Dr. Manfred Schmidt, and Dr. Annette Deichmann with the participation of the German Cancer Research Center (DKFZ) Heidelberg, GeneWerk is a cell and gene therapy testing laboratory focused on providing preclinical and clinical trial patient sample analysis services.  The company is recognized as a leading provider of vector integration site analysis (ISA) services, a method that was developed by the company’s founders and that the FDA and EMA recommend performing after the administration of both integrating and non-integrating cell and gene therapies.  For more information, please visit www.genewerk.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com.

Categories: News

Tags:

Ampersand Capital Partners Acquires American Laboratory Products Company

SALEM, N.H., Sept. 21, 2020 /PRNewswire/ — American Laboratory Products Company, Ltd. (ALPCO), a specialty in vitro diagnostics company, today announced the majority recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment will be used to support ALPCO’s worldwide growth initiatives, including the expansion of the company’s diagnostics test kit offering, broadening the company’s geographic presence, and fueling internal R&D product development and production operations.

ALPCO is a Salem, NH-based in vitro diagnostics company that offers specialty immunoassay products (IVD and RUO) primarily focused on the clinical gastroenterology and diabetes research segments. Founded in 1990 by Richard and Jan Conley as an importer and distributor of immunoassay-based products for the North American life science markets, the company is now a leading global provider of both distributed and proprietary diagnostics products. As part of the transaction, Richard and Jan Conley will remain shareholders in the company, and Sean Conley will continue to lead the business as CEO. ALPCO has also announced the appointment of Larry McCarthy, PhD as Chairman of the company’s Board of Directors.

“We are very excited to partner with Sean and his team to continue to grow the business,” stated Eric Lev, General Partner at Ampersand. “With our operating and investment experience within the laboratory products and diagnostics markets, coupled with an injection of growth capital, we believe that ALPCO is poised to be a market leader in specialty immunoassay products worldwide.”

Sean Conley added: “We have always been committed to offering our customers the solutions they need to both advance the quality of care and enable better medical research. I am confident that this partnership with Ampersand will allow us to grow as an organization and better serve our customers as we invest in our infrastructure and service offering.”

About American Laboratory Products Company

Founded in 1990, American Laboratory Products Company (ALPCO) began as an importer and distributor of immunoassay-based products for the North American life science markets. The company is now a premier provider of proprietary and distributed diagnostics solutions, with over 60 collaborating partners from around the globe. While our vision has evolved to serve a broader segment of life science research and healthcare professionals, our mission to deliver “Scientific Solutions for Life” remains the same.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience in seeking to build value and drive strong long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com.

Categories: News

Tags:

Pembroke VCT launches new £20m offer with over allotment facility for further £20m

Pembroke

Pembroke VCT, the venture capital trust focused on building the consumer brands of tomorrow, has launched a new share offer to raise up to £40 million (an initial £20 million,with an over-allotment facility for a further £20 million).The additional cashwill allow the company to grow its existing portfolio and take advantage of a healthy pipeline of prospective investment opportunities.Pembroke VCT gives investors the opportunity to share in the growth of some of the UK’s most exciting and innovative smaller companies, across industries with strong growth prospects. It has total assets of over £110million (31August 2020). Since its launch in 2012, Pembroke VCT has invested£75million in45 companies,helping strong management teams realise their vision for building consumer-focused brands.New investors will gain immediate access to a maturing portfolio of growing businesses and to a well‑established dividend‑paying VCT. The portfolio includeshigh growth, innovative brands–such as Plenish, Popsa, Kinteract, ME+EMand Pasta Evangelists–in the design, education, food, beverage & hospitality, wellness, digital services and media sectors.Additionally, Pembroke intends to use the funds raised to make a number of follow‑on investments in portfolio companies, where further capital will accelerate their growth plans. Pembroke partners with founders and its ‘Stepping Stone’ investment process provides additional funding to take advantage of growth opportunities that emerge during the journey. Andrew Wolfson, CEO of Pembroke Investment Managers LLPcommented; “Weinvest in exceptional foundersthat we believe in,and work alongside themto supporttheircontinued growth through our strategic and operational expertise.This new offer will not only allow us to growour existing portfolio, but also to invest in new companies that we believe have the potential to become the consumer brands of tomorrow.”

-ENDS-NOTES

TO EDITORS

Pembroke VCT

Pembroke VCT plc, managed by Pembroke Investment Managers LLP, is a VCT with a difference –offering much more than capital. Pembroke finds exceptional founders to grow the consumer brands of tomorrow, across industries with exciting growth prospects. Pembroke only invests in companies where it can add value over and above simply providing capital, where it is confident its resources and experience can be most instrumental in their growth. The VCT gives investors the opportunity to share in the growth of some of the UK’s most exciting and innovative smaller companiesin the design, education, food, beverage & hospitality, wellness, digital services and media sectors.

Andrew Wolfson, CEO, Pembroke Investment Managers LLP

CEO Andrew Wolfson is responsible for executing the firm’s strategy, leading the investment team, deal origination and supporting portfolio companies. Andrew sits on the board of a number of Pembroke’s investments. Prior to the launch of Pembroke, Andrew was a Director at Oakley Capital and worked with smaller portfolio companies including KX and James Perse. Before joining Oakley, Andrew ran several businesses working across a breadth of sectors from hospitality to manufacturing and telecoms. Andrew is also a director of Benesco Charity Limited, and a trustee of The Charles Wolfson Charitable Trust.

Press Office

Zoe Powelle:zpowell@sharecomms.co.ukdd: 020 7071 3932m: 07866 639014

Sarah Plevnike:splevnik@sharecomms.co.ukdd:020 7074 3571m:07789 725585

Categories: News

Tags:

Forbion portfolio company, Inflazome acquired by Roche

Forbion

Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
• Acquisition gives Roche full rights to the Inflazome portfolio
• Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation
• Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments

Naarden, The Netherlands 21 September 2020: Forbion, a leading European life sciences venture capital firm, notes that its portfolio company Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). Inflazome’s shareholders have received an upfront payment of €380 million and are eligible to receive additional contingent payments to be made based on the achievement of certain predetermined milestones.

Inflazome was founded in 2016 by leading medical researchers Prof Matt Cooper (University of Queensland, Australia) and Prof Luke O’Neill (Trinity College Dublin, Ireland). The company is a leader in the development of inflammasome inhibitors.

The acquisition gives Roche full rights to Inflazome’s entire portfolio which is composed of clinical and preclinical orally available small molecule NLRP3 inhibitors. Roche intends to further develop NLRP3 inhibitors across a wide variety of indications with high unmet medical need.

Matt Cooper, Chief Executive Officer, Inflazome, commented “We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications. With Inflazome now part of the Roche organization, Inflazome’s pioneering drugs are well positioned to be developed quickly and effectively so they can help patients suffering from debilitating diseases.”

Marco Boorsma, General Partner, Forbion, said “Having been the lead investor in Inflazome’s Series B fundraising in 2018, we are pleased to see this deal closed with Roche, a trusted partner, which leaves the Company well-positioned to unlock the potential of its NLRP3 inhibitors. We believe this transaction reflects well on the Forbion team to help companies grow and develop, and delivering excellent returns to our funds. We are delighted to have been part of Inflazome’s journey and will follow the development of Inflazome‘s promising compounds with great interest.”

Lazard acted as financial advisor and Goodwin Procter and Byrne Wallace acted as legal counsel to Inflazome.

For more information please contact:

Forbion contact:
Marco Boorsma, General Partner
P: +31 (35) 699 3000

Instinctif Partners for Forbion
Melanie Toyne-Sewell/Phillip Marriage/Kiki Zaccagnini
Email: forbion@instinctif.com

Notes to Editors

About Forbion
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Singapore. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 66 companies. Forbion manages well over EUR 1.25 billion across ten funds.

Forbion is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients.

Its investors include the EIF, through its European Recovery Programme (ERP), LfA, Dutch Venture Initiative (DVI), AMUF and EFSI facilities and KfW Capital through the Programme, “ERP – Venture Capital Fondsinvestments”.

Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany.
For more information, please visit: www.forbion.com.

About Inflazome
Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome has a portfolio of orally available small molecule NLRP3 inhibitors, with lead molecules having successfully completed Phase I clinical trials, as well as several high potential earlier-stage programmes.

Inflazome has raised €55m in Venture Capital financing from leading investors Forbion, Longitude Capital, Fountain Healthcare Partners and Novartis Venture Fund.

Inflazome is headquartered in Dublin, Ireland.

About the NLRP3 Inflammasome
Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases.

Categories: News

Tags:

Nordic Capital-backed Conscia announces four acquisitions in a week expanding its presence within cyber-security, cloud transformation and managed services

Nordic Capital

September 21 2020
Nordic Capital-backed Conscia announces four acquisitions in a week expanding its presence within cyber-security, cloud transformation and managed services Image

 

Conscia, the expert in IT infrastructure and security solutions has announced four acquisitions in the past week: Danish cyber-security specialist Credocom, Danish VMware consulting firm NetIT, Dutch cloud services provider Damecon and Swedish cloud services company SECOA. 

Nordic Capital acquired Conscia in Spring 2019 in order to support the company’s fast-paced expansion in Europe, through an active buy and build strategy in new and existing geographies.  In addition to the acquisitions announced the last week, Conscia acquired German technology company xevIT in Autumn 2019, taking the total number of acquisitions since Nordic Capital acquired Conscia to five, strengthening its market leading position and service offering.

Founded in Brøndby, Denmark in 2003, Conscia is one of the leading players in the Northern European IT infrastructure space within complex infrastructure solutions and managed services. Conscia builds and services some of Europe’s most complex IT security and networking infrastructures, and notably is recognised as one of the strongest integrators of Cisco solutions. Customers include some of the largest organisations within financial services, healthcare, and public sector organisations.

“Nordic Capital is delighted to be part of Conscia’s growth journey supporting the business through its continued international expansion strategy whilst also strengthening its offering within cybersecurity, multi-cloud and managed services.  We are seeing increased interest from customers who want to make sure that their IT infrastructure is flexible, scalable and can withstand cyber-security attacks whilst also ensuring that their digital foundation is strong enough to support their future business opportunities,” said Fredrik Näslund, Partner, Nordic Capital Advisors.

The acquisitions further cement Nordic Capital’s expertise and outstanding track record in the Technology & Payments sector. Nordic Capital has made 17 Technology & Payment platform investments to date as well as many add-on acquisitions since its first acquisition in the sector in 2001.

 

About Conscia

Conscia is a Network of Knowledge and an ICT service provider that specialises in cyber security, IT infrastructure solutions, and managed services. As a trusted advisor Conscia strives to support the customers ‘business-critical IT infrastructure’ across the entire value chain from design, implementation, operation and optimization. The ambition is supported by profound technical competencies and insight, which is displayed through the unique customer portal, this also forms the basis for the best customer experiences and the highest customer satisfaction in the industry. Another strategic goal for Conscia is to be the most attractive workplace for talented IT infrastructure specialists in Europe. Currently Conscia Group has more than 750 employees across six countries (Denmark, Sweden, Norway, Germany, Netherlands, and Slovenia), with an annual turnover of approximately DKK 2,5bn DKK (€335mm). For more information, please visit Conscia.com

 

Categories: News

Tags:

Carlyle Makes Strategic Growth Investment in TriNetX; Acquires Majority Stake in Leading Global Health Research Network

Carlyle

Investment will Accelerate Development of New Clinical Research Capabilities for Healthcare Organizations and Life Sciences Customers, With the Aim of Capitalizing on Both Organic and Inorganic Growth Opportunities

NEW YORK and Cambridge, MA, September 21, 2020 — TriNetX (www.trinetx.com), the leading global health research network optimizing clinical research to bring new therapies to market faster, today announced global investment firm The Carlyle Group (NASDAQ: CG) has made a strategic growth investment and will acquire a majority stake in the Company. Terms of the transaction were not disclosed.

Since its founding in 2013, TriNetX has built the largest global network of research hospitals and academic institutions, top biotech and pharmaceutical companies, contract research organizations (CROs) and other specialty data partners. TriNetX is powered by an impressive network of 170 healthcare organizations in 30 countries and used by more than 40 life sciences organizations including 15 of the world’s top 20 pharmaceutical companies.

“Our goal is to be on the desktop of every healthcare researcher in the world,” said Gadi Lachman, CEO of TriNetX. “To accomplish this we need to continue to develop solutions to support clinical research at our healthcare organizations and bring more global data and technologies such as AI, machine learning and analytics to researchers so that they can ask more questions and generate more real-world evidence. Carlyle’s investment accelerates our growth plans and will shorten the time it takes to turn our vision into reality.”

TriNetX enables researchers to apply a data-driven approach to health research by providing web-based, on-demand access to harmonized global electronic health record (EHR) and claims data with a suite of highly intuitive analytics. TriNetX is utilized in all parts of the drug development cycle, including protocol design and feasibility, site selection and patient identification for clinical trials, as well as serving clinical research for drugs already in the market to help researchers understand efficacy, risks and other market dynamics and to generate real-world evidence (RWE) to support hypothesis and decision making, in real-time.

The longitudinal clinical and claims data representing over 400 million patients available through TriNetX is mapped to controlled terminology and consists of clinical facts from hundreds of healthcare organizations around the world, deep specialty data for all therapeutic areas, including COVID-19, cardiovascular, oncology, and rare disease, and linked medical claims, pharmacy claims and EHR data.

“With a deep clinical focus and a highly scalable data strategy, we believe TriNetX is well positioned for continued organic and inorganic growth opportunities,” said Joe Bress, a Principal specializing in healthcare at The Carlyle Group. “We’re excited to partner with Gadi and the TriNetX management team to help expand their global footprint and continue investing in the company’s mission to advance the collective understanding of human health.”

The investment in TriNetX is a continuation of Carlyle’s long-term global commitment to healthcare, in which it has invested more than $15 billion of equity since inception. Equity capital for the investment came from Carlyle Partners VII, an $18.5 billion fund that makes majority and strategic minority investments primarily in the U.S. in targeted industries, including healthcare.

SVB Leerink served as exclusive financial advisor to TriNetX.

####

About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across four business segments: Corporate Private Equity, Real Assets, Global Credit and Investment Solutions. With $221 billion of assets under management as of June 30, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs more than 1,800 people in 31 offices across six continents. Further information is available at www.carlyle.com. Follow The Carlyle Group on Twitter @OneCarlyle.

About TriNetX 

TriNetX is the global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to optimize protocol design and feasibility, site selection, patient recruitment, and enable discoveries through the generation of real-world evidence. The TriNetX platform is HIPAA and GDPR compliant. For more information, visit TriNetX at http://www.trinetx.com or follow @TriNetX on Twitter.

Media Contacts:

Brittany Berliner
Brittany.Berliner@carlyle.com
+1 (212) 813 4839

Jennifer Haas
Jennifer.haas@trinetx.com
+ 1 (978) 697 3921

Categories: News

Tags:

AURELIUS subsidiary Scholl Footwear sells its Australian distribution business to Global Footcare Group

Aurelius Capital

Munich / Melbourne / Milan, September 21, 2020 – Scholl Footwear, a subsidiary of AURELIUS Equity Opportunities SE & Co. KGaA (ISIN: DE000A0JK2A8), is selling its Australian distribution business to the Global Footcare Group based in Coomera, Queensland, Australia. Global Footcare is a strategic buyer and specializes in the distribution and marketing of comfort footwear. The company will drive sales of Scholl shoes in Australia and New Zealand, via wholesale and specialist channels like pharmacy, health professionals, as well as sports and shoe retail outlets.

The sales transaction is part of Scholl Footwear’s global strategy of leveraging strong regional partners and industry specialists to generate additional growth and further improve earnings through licensing and distribution partnerships.

In Europe, Scholl Footwear operates from its headquarters in Milan, Italy, from which design and collection development, marketing, distribution and licensing activities are managed. Its Asian business is driven via the APAC hub, with the expansion of licensing partnerships playing the leading role.

“Global Footcare is the most capable partner for marketing our products in Australia and New Zealand, especially in view of its already long established partnership as a Scholl Footwear distributor across the medical channel in Australia and New Zealand as well as its local presence and proximity to customers. We’re looking forward to working jointly on future growth,” said Tobias Klaiber, the responsible executive for Scholl Footwear. “We’re considering similar concepts for other markets in the APAC region as well.”

Categories: News

Tags: